Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats

被引:0
|
作者
Manickam Aravagiri
Stephen R. Marder
机构
[1] Psychopharmacology Unit,
[2] University of California at Los Angeles,undefined
[3] VA Greater Los Angeles Healthcare System,undefined
[4] Building 210,undefined
[5] #15,undefined
[6] 11301 Wilshire Boulevard,undefined
[7] Los Angeles,undefined
[8] CA 90073,undefined
[9] USA,undefined
来源
Psychopharmacology | 2002年 / 159卷
关键词
Risperidone 9-Hydroxyrisperidone Pharmacokinetics Rat Oral dose Plasma Brain Tissue LC-MS-MS;
D O I
暂无
中图分类号
学科分类号
摘要
Rationale: Following an oral dose of risperidone (RSP), concentrations of its major metabolite 9-hydroxyrisperidone (9-OHRSP) were high in plasma and tissues but disproportionately lower in the brain compared to RSP, indicating that 9-OHRSP may have different pharmacokinetic properties. Objectives: To investigate non-compartmental pharmacokinetics of RSP and 9-OHRSP in plasma, brain and other tissues after separate administration of a single oral dose of 6 mg/kg RSP and 9-OHRSP to rats. Methods: Plasma, brain, liver, lung, kidney and spleen tissues were collected at pre-dose and at 0.5, 1, 2, 5, 6, 12, 24, 36 and 48 h post-dose, homogenized in saline and assayed for RSP and 9-OHRSP using a sensitive and specific liquid chromatography tandem mass spectrometry method. Results: The concentration-time curve of RSP and 9-OHRSP showed that they were readily absorbed and followed a multiphase elimination pattern. The terminal elimination half-life (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}% MathType!MTEF!2!1!+- % feaaeaart1ev0aaatCvAUfKttLearuavTnhis1MBaeXatLxBI9gBam % XvP5wqSXMqHnxAJn0BKvguHDwzZbqegm0B1jxALjhiov2DaeHbuLwB % Lnhiov2DGi1BTfMBaebbnrfifHhDYfgasaacH8srps0lbbf9q8WrFf % euY-Hhbbf9v8qqaqFr0xc9pk0xbba9q8WqFfea0-yr0RYxir-Jbba9 % q8aq0-yq-He9q8qqQ8frFve9Fve9Ff0dmeaabaqaciaacaGaaeqaba % WaaqaafaaakeaacqWG0baDdaWgaaWcbaWaaSGaaeaacqaIXaqmaeaa % cqaIYaGmaaaabeaaaaa!3E81!\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$t_{{\raise0.7ex\hbox{$1$} \!\mathord{\left/ {\vphantom {1 2}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{$2$}}} $$\end{document} ) of RSP after the RSP dose was longest in the liver (17.6 h) and shortest in the spleen (1.2 h). The \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}% MathType!MTEF!2!1!+- % feaaeaart1ev0aaatCvAUfKttLearuavTnhis1MBaeXatLxBI9gBam % XvP5wqSXMqHnxAJn0BKvguHDwzZbqegm0B1jxALjhiov2DaeHbuLwB % Lnhiov2DGi1BTfMBaebbnrfifHhDYfgasaacH8srps0lbbf9q8WrFf % euY-Hhbbf9v8qqaqFr0xc9pk0xbba9q8WqFfea0-yr0RYxir-Jbba9 % q8aq0-yq-He9q8qqQ8frFve9Fve9Ff0dmeaabaqaciaacaGaaeqaba % WaaqaafaaakeaacqWG0baDdaWgaaWcbaWaaSGaaeaacqaIXaqmaeaa % cqaIYaGmaaaabeaaaaa!3E81!\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$t_{{\raise0.7ex\hbox{$1$} \!\mathord{\left/ {\vphantom {1 2}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{$2$}}} $$\end{document} of 9-OHRSP after the RSP dose was shorter in plasma (3.4 h) and other tissues (~8–11 h) than that for RSP but it was longer in the spleen. However, the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}% MathType!MTEF!2!1!+- % feaaeaart1ev0aaatCvAUfKttLearuavTnhis1MBaeXatLxBI9gBam % XvP5wqSXMqHnxAJn0BKvguHDwzZbqegm0B1jxALjhiov2DaeHbuLwB % Lnhiov2DGi1BTfMBaebbnrfifHhDYfgasaacH8srps0lbbf9q8WrFf % euY-Hhbbf9v8qqaqFr0xc9pk0xbba9q8WqFfea0-yr0RYxir-Jbba9 % q8aq0-yq-He9q8qqQ8frFve9Fve9Ff0dmeaabaqaciaacaGaaeqaba % WaaqaafaaakeaacqWG0baDdaWgaaWcbaWaaSGaaeaacqaIXaqmaeaa % cqaIYaGmaaaabeaaaaa!3E81!\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$t_{{\raise0.7ex\hbox{$1$} \!\mathord{\left/ {\vphantom {1 2}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{$2$}}} $$\end{document} of 9-OHRSP after the 9-OHRSP dose was shorter in most tissues as compared to the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}% MathType!MTEF!2!1!+- % feaaeaart1ev0aaatCvAUfKttLearuavTnhis1MBaeXatLxBI9gBam % XvP5wqSXMqHnxAJn0BKvguHDwzZbqegm0B1jxALjhiov2DaeHbuLwB % Lnhiov2DGi1BTfMBaebbnrfifHhDYfgasaacH8srps0lbbf9q8WrFf % euY-Hhbbf9v8qqaqFr0xc9pk0xbba9q8WqFfea0-yr0RYxir-Jbba9 % q8aq0-yq-He9q8qqQ8frFve9Fve9Ff0dmeaabaqaciaacaGaaeqaba % WaaqaafaaakeaacqWG0baDdaWgaaWcbaWaaSGaaeaacqaIXaqmaeaa % cqaIYaGmaaaabeaaaaa!3E81!\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$t_{{\raise0.7ex\hbox{$1$} \!\mathord{\left/ {\vphantom {1 2}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{$2$}}} $$\end{document} of 9-OHRSP after the RSP dose. The area under the concentration-time curve (AUC) of RSP and 9-OHRSP was 6–67 times higher in the plasma and tissues than in the brain. AUCs of 9-OHRSP in tissues after the RSP dose were 2–5 times higher than those for RSP, except in the brain, where AUCs of RSP and 9-OHRSP were similar. Conclusion: Pharmacokinetics of 9-OHRSP in many tissues were different after RSP and 9-OHRSP doses. The reason for disproportionate brain levels of 9-OHRSP is not clear. The overall exposure to active drug in the brain as represented by AUC was similar after the RSP and 9-OHRSP doses and the 9-OHRSP is probably an equal contributor to the pharmacological actions of RSP.
引用
收藏
页码:424 / 431
页数:7
相关论文
共 50 条
  • [1] Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats
    Aravagiri, M
    Marder, SR
    PSYCHOPHARMACOLOGY, 2002, 159 (04) : 424 - 431
  • [2] Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats
    Lee, Kyoung Sin
    Chae, Song Wha
    Park, Joon Hee
    Park, Jung Hyun
    Choi, Jong Min
    Rhie, Sandy
    Lee, Hwa Jeong
    XENOBIOTICA, 2013, 43 (03) : 303 - 310
  • [3] The influence of age on plasma levels of risperidone and 9-hydroxyrisperidone
    Aichhorn, W
    Marksteiner, J
    Weiss, U
    Walch, T
    Kemmler, G
    Zernig, G
    Saria, A
    Geretsegger, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S271 - S272
  • [4] Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine
    Spina, E
    Avenoso, A
    Facciolà, G
    Scordo, MG
    Ancione, M
    Madia, A
    THERAPEUTIC DRUG MONITORING, 2001, 23 (03) : 223 - 227
  • [5] Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia
    Zhou, Zhi-ling
    Li, Huan-de
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 218 - 218
  • [6] Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia
    Zhi-ling Zhou
    Xin Li
    Huai-yan Peng
    Xi-yong Yu
    Ming Yang
    Feng-li Su
    Feng Wang
    Rong-hua Zhu
    Chun-yu Deng
    Qiu-xiong Lin
    Chuan-yue Wang
    Wen-biao Li
    Shu-guang Lin
    Huan-de Li
    Acta Pharmacologica Sinica, 2006, 27 : 381 - 386
  • [7] Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia
    Zhou, ZL
    Li, X
    Peng, HY
    Yu, XY
    Yang, M
    Su, FL
    Wang, F
    Zhu, RH
    Deng, CY
    Lin, QX
    Wang, CY
    Li, WB
    Lin, SG
    Li, HD
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (03) : 381 - 386
  • [8] Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia
    Zhi-ling ZHOU~2 Xin LI~3 Huai-yan PENG~4 Xi-yong YU~2 Ming YANG~2 Feng-li SU~1 Feng WANG~1 Rong-hua ZHU~1 Chun-yu DENG~2 Qiu-xiong LIN~2 Chuan-yue WANG~5 Wen-biao LI~5 Shu-guang LIN~2 Huan-de LI~(1
    ~2Research Center of Medical Science
    ~3Vascular Surgery Department
    ~4Department of Clinical Laboratory
    ~5Affiliated Beijing An Ding Hospital
    ActaPharmacologicaSinica, 2006, (03) : 381 - 386
  • [9] Plasma concentrations of risperidone and 9-hydroxyrisperidone:: Effect of comedication with carbamazepine or valproate
    Spina, E
    Avenoso, A
    Facciolà, G
    Salemi, M
    Scordo, MG
    Giacobello, T
    Madia, AG
    Perucca, E
    THERAPEUTIC DRUG MONITORING, 2000, 22 (04) : 481 - 485
  • [10] Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS
    Cabovska, B.
    Cox, S. L.
    Vinks, A. A.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2): : 497 - 504